Open AccessMetformin throughout Pregnancy in Women with Polycystic Ovary Syndrome: Safety and Advantages
Author(s) -
Palshetkar Nandita P,
Pai Hrishikesh D,
Manisha Takhtani,
SaxeidhiBharti Bansal,
Dalal Rutvij J
Publication year - 2011
Publication title -
international journal of infertility and fetal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.102
H-Index - 6
eISSN - 2229-3833
pISSN - 2229-3817
DOI - 10.5005/jp-journals-10016-1019
Subject(s) - medicine , polycystic ovary , metformin , incidence (geometry) , pregnancy , obstetrics , gestational diabetes , hypoglycemia , abortion , gestation , gynecology , diabetes mellitus , insulin resistance , endocrinology , physics , biology , optics , genetics
Objective To study the incidence of spontaneous abortions, congenital malformations, neonatal and maternal hypoglycemia after metformin therapy in pregnancy. Design Prospective study. Setting Outpatient. Patient(s) 56 women previously oligomenorrheic, nondiabetic women with polycystic ovarian syndrome, who conceived while on metformin. Intervention(s) Metformin 1 to 1.5 gm/day throughout pregnancy. Main outcome Incidence of 1st trimester abortions, gestational diabetes, teratogenicity and maternal complications, like gastritis and hypoglycemia. Results On metformin, the incidence of 1st trimester abortion was 11% and the incidence of gestational diabetes was 7%, which is much lower than the incidence otherwise cited for PCOS women. No major congenital abnormalities were observed. Conclusion Metformin therapy in pregnancy reduces the otherwise high incidence of 1st trimester abortions, and gestational diabetes in PCOS women is tolerated well and is not found to be teratogenic.